KBC Group NV Sells 199,751 Shares of Lantheus Holdings, Inc. (NASDAQ:LNTH)

KBC Group NV reduced its position in Lantheus Holdings, Inc. (NASDAQ:LNTH - Free Report) by 99.1% during the 3rd quarter, according to the company in its most recent filing with the Securities and Exchange Commission (SEC). The fund owned 1,898 shares of the medical equipment provider's stock after selling 199,751 shares during the period. KBC Group NV's holdings in Lantheus were worth $208,000 at the end of the most recent quarter.

A number of other hedge funds and other institutional investors also recently made changes to their positions in LNTH. Russell Investments Group Ltd. boosted its position in Lantheus by 10.4% during the first quarter. Russell Investments Group Ltd. now owns 37,708 shares of the medical equipment provider's stock worth $2,347,000 after purchasing an additional 3,560 shares during the period. State Board of Administration of Florida Retirement System boosted its position in shares of Lantheus by 8.6% in the first quarter. State Board of Administration of Florida Retirement System now owns 21,088 shares of the medical equipment provider's stock valued at $1,313,000 after acquiring an additional 1,670 shares during the period. Vanguard Group Inc. boosted its position in shares of Lantheus by 5.6% in the first quarter. Vanguard Group Inc. now owns 7,362,969 shares of the medical equipment provider's stock valued at $458,271,000 after acquiring an additional 389,828 shares during the period. CANADA LIFE ASSURANCE Co boosted its position in shares of Lantheus by 30.5% in the first quarter. CANADA LIFE ASSURANCE Co now owns 50,078 shares of the medical equipment provider's stock valued at $3,116,000 after acquiring an additional 11,696 shares during the period. Finally, Healthcare of Ontario Pension Plan Trust Fund bought a new stake in shares of Lantheus in the first quarter valued at approximately $1,432,000. 99.06% of the stock is owned by hedge funds and other institutional investors.

Analyst Upgrades and Downgrades

Several research firms have recently weighed in on LNTH. JMP Securities reduced their price objective on Lantheus from $125.00 to $112.00 and set a "market outperform" rating for the company in a research report on Thursday, November 7th. Redburn Atlantic assumed coverage on Lantheus in a research note on Tuesday, September 3rd. They set a "buy" rating and a $175.00 price objective for the company. B. Riley increased their price objective on Lantheus from $105.00 to $146.00 and gave the stock a "buy" rating in a research note on Thursday, July 25th. StockNews.com upgraded Lantheus from a "hold" rating to a "buy" rating in a research note on Friday, November 8th. Finally, Truist Financial restated a "buy" rating and issued a $120.00 target price (down from $135.00) on shares of Lantheus in a research note on Friday, November 8th. One analyst has rated the stock with a hold rating and nine have issued a buy rating to the stock. According to data from MarketBeat.com, Lantheus has an average rating of "Moderate Buy" and a consensus target price of $122.50.

Lantheus Stock Up 8.8 %

Lantheus stock opened at $86.45 on Thursday. The business's 50-day simple moving average is $103.76 and its 200 day simple moving average is $96.59. The stock has a market cap of $6.01 billion, a price-to-earnings ratio of 14.38 and a beta of 0.51. Lantheus Holdings, Inc. has a 12-month low of $50.20 and a 12-month high of $126.89.

Lantheus Profile

Lantheus Holdings, Inc develops, manufactures, and commercializes diagnostic and therapeutic products that assist clinicians in the diagnosis and treatment of heart, cancer, and other diseases worldwide. It provides DEFINITY, an injectable ultrasound enhancing agent used in echocardiography exams; TechneLite, a technetium generator for nuclear medicine procedures; Xenon-133, a radiopharmaceutical gas to assess pulmonary function; Neurolite, an injectable imaging agent to identify the area within the brain where blood flow has been blocked or reduced due to stroke; Cardiolite, an injectable Tc-99m-labeled imaging agent to assess blood flow to the muscle of the heart; and PYLARIFY, an F 18-labelled PSMA-targeted PET imaging agent used for imaging of PSMA positive-lesions in men with prostate cancer.